ICML 2019 | Providing a PLATFORM: first results for liso-cel plus durvalumab in R/R B-cell NHL

Tanya Siddiqi

Tanya Siddiqi, MD, City of Hope, Duarte, CA, discusses the first results of the PLATFORM trial (NCT03310619). She discusses the safety of lisocabtagene maraleucel given with durvalumab to patients with relapsed/refractory aggressive B-cell non-Hodgkin lympoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics